PMID- 38041095
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231205
IS  - 1743-7075 (Print)
IS  - 1743-7075 (Electronic)
IS  - 1743-7075 (Linking)
VI  - 20
IP  - 1
DP  - 2023 Dec 1
TI  - Amelioration of Atherosclerosis by lycopene is linked to the modulation of gut 
      microbiota dysbiosis and related gut-heart axis activation in high-fat diet-fed 
      ApoE(-/-) mice.
PG  - 53
LID - 10.1186/s12986-023-00772-x [doi]
LID - 53
AB  - BACKGROUND: Interplay between gut microbiota and heart, termed "gut-heart" axis, 
      has a crucial role in the pathogenesis of atherosclerosis. Our previous study 
      showed that lycopene possesses anti-inflammatory and anti-atherosclerotic 
      effects, but its link to the gut microbiota is poorly understood. Herein, we 
      surmised that lycopene could regulate the gut microbiota, exert 
      anti-atherosclerotic effect by regulating the "gut-heart" axis. METHODS: Male 
      ApoE(-/-) mice were fed a high-fat diet (HFD) with or without lycopene (0.1% w/w) 
      for 19 weeks. Gut microbiota was analyzed by 16 S rRNA sequencing, the protein 
      levels of zonula occludens-1 (ZO-1), occludin, toll-like receptor 4 (TLR4) and 
      phospho-nuclear factor-kappaB (NF-kappaB) p65 were measured by Western blotting, the 
      levels of serum inflammatory factors including monocyte chemotactic protein 1 
      (MCP-1), tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6 were 
      assayed using ELISA kits. Also, the concentrations of serum lipopolysaccharide 
      (LPS), D-lactic acid (D-LA) and diamine peroxidase (DAO) were measured through 
      ELISA method. RESULTS: The aortic sinus sections revealed that lycopene 
      supplementation significantly reduced the extent of atherosclerotic lesions and 
      inhibited atherosclerosis development caused by HFD. The analysis of gut 
      microbiota showed that lycopene reduced the ratio of Firmicutes/Bacteroides and 
      increased the relative abundance of Verrucomicrobia, Akkermansia and 
      Alloprevotella, which were related to elevated intestinal barrier function and 
      reduced inflammation. Moreover, lycopene up-regulated the expression of 
      intestinal ZO-1 and occludin and decreased serum LPS, D-LA and DAO levels. In 
      addition, lycopene inhibited the expression of TLR4 and phospho-NF-kappaB p65 in 
      aortic sinus plaque, serum MCP-1, TNF-alpha, IL-1beta, and IL-6 levels were also lowered 
      by lycopene treatment. CONCLUSIONS: Our results indicated the protective effect 
      of lycopene against atherosclerosis induced by HFD and further revealed that its 
      mechanism might be its prebiotic effect on maintaining gut microbiota homeostasis 
      and improving intestinal barrier function, consequently reducing serum 
      LPS-triggered inflammatory response in the heart.
CI  - (c) 2023. The Author(s).
FAU - Tu, Tengcan
AU  - Tu T
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      510280, China.
AD  - Department of Cardiology, The Sixth Affiliated Hospital, School of Medicine, 
      South China University of Technology, 120 Guidan Road, Foshan, 528200, Guangdong 
      Province, China.
FAU - Liu, Hao
AU  - Liu H
AD  - Department of Cardiology, The Seventh Affiliated Hospital of Southern Medical 
      University, Foshan, 528244, China.
FAU - Liu, Zhenhao
AU  - Liu Z
AD  - Department of Cardiology, Ganzhou People's Hospital, Ganzhou, 341000, China.
FAU - Liang, Yunyi
AU  - Liang Y
AD  - Health Management Center, The Sixth Affiliated Hospital, School of Medicine, 
      South China University of Technology, Foshan, 528200, China.
FAU - Tan, Chujun
AU  - Tan C
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      510280, China.
FAU - Feng, Dan
AU  - Feng D
AD  - Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of 
      Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, 
      China. fengdan3@mail.sysu.edu.cn.
FAU - Zou, Jun
AU  - Zou J
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      510280, China. zoujun961@163.com.
AD  - Department of Cardiology, The Sixth Affiliated Hospital, School of Medicine, 
      South China University of Technology, 120 Guidan Road, Foshan, 528200, Guangdong 
      Province, China. zoujun961@163.com.
LA  - eng
GR  - 81973019/National Natural Science Foundation of China/
GR  - 2022A1515011610, 2020A1515011167/Natural Science Foundation of Guangdong 
      Province/
GR  - 2022A1515012268, 2018A030313782/Natural Science Foundation of Guangdong Province/
PT  - Journal Article
DEP - 20231201
PL  - England
TA  - Nutr Metab (Lond)
JT  - Nutrition & metabolism
JID - 101231644
PMC - PMC10691047
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Gut microbiota
OT  - Lycopene
OT  - Nuclear factor-kappaB
OT  - Toll-like receptor 4
COIS- The authors declare no competing interests. All authors declare that they have no 
      conflict of interest.
EDAT- 2023/12/02 00:41
MHDA- 2023/12/02 00:42
PMCR- 2023/12/01
CRDT- 2023/12/01 23:58
PHST- 2023/08/11 00:00 [received]
PHST- 2023/11/21 00:00 [accepted]
PHST- 2023/12/02 00:42 [medline]
PHST- 2023/12/02 00:41 [pubmed]
PHST- 2023/12/01 23:58 [entrez]
PHST- 2023/12/01 00:00 [pmc-release]
AID - 10.1186/s12986-023-00772-x [pii]
AID - 772 [pii]
AID - 10.1186/s12986-023-00772-x [doi]
PST - epublish
SO  - Nutr Metab (Lond). 2023 Dec 1;20(1):53. doi: 10.1186/s12986-023-00772-x.